Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

This study has been terminated.

( NINDS DSMB recommended trial be terminated for futility after reviewing an interim analysis of 84 subjects. )

Study NCT00818389 Information provided by Massachusetts General Hospital

First Received on January 6, 2009. Last Updated on March 18, 2011 History of Changes

Results First Received: May 10, 2010

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Crossover Assignment; Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor); Primary Purpose: Treatment
Condition:	Amyotrophic Lateral Sclerosis
Interventions:	Drug: Lithium Carbonate Drug: Riluzole Drug: placebo

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Between January 2009 to June 2009, 97 patients were screened and 84 subjects were randomized at 21 clinical sites; 11 in the United States and 10 in Canada. All sites were members of the Northeast ALS Consortium (NEALS) and/or the Canadian ALS Consortium (CALS).

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
All patients were required to be on a stable dose of riluzole for at least 30 days prior to screening. 13 subjects failed screening: 3 due to low lung function test results, 3 due to prohibited medications,3 due to study closure, 2 due to abnormal lab test results and 1 due to death unrelated to the study.

Reporting Groups

	Description
Lithium + Riluzole	Subjects randomized to lithium + riluzole were required to be taking riluzole 50 milligrams (mg) twice per day at least 30 days prior to the screening visit and during the trial. Lithium carbonate and matching placebo were supplied in 150 mg capsules. Dosing started at 450 mg/day (1 capsule taken in the a.m. and 2 capsules taken in the p.m.), titrated to maintain plasma lithium levels of 0.4 - 0.8 milliequivalent per liter (mEq/L). The number of capsules taken per day was titrated individually for each patient based on blood testing to maintain plasma levels of lithium = 04. - 0.8 milliequivalent per liter (mEq/L).
Placebo + Riluzole	Participants randomized to placebo + riluzole were required to be taking riluzole 50 milligrams (mg) twice per day at least 30 days prior to the screening visit and during the trial. Matching placebo was supplied in 150 mg capsules. Dosing started at 450 mg/day (1 capsule in the a.m. and 2 capsules in the p.m). Paired sham dosage modifications were made for placebo subjects, i.e. all subjects randomized to placebo were 'paired' with a lithium subject and underwent identical dosage changes to maintain blinding.

Description

Lithium + Riluzole

Subjects randomized to lithium + riluzole were required to be taking riluzole 50 milligrams (mg) twice per day at least 30 days prior to the screening visit and during the trial. Lithium carbonate and matching placebo were supplied in 150 mg capsules. Dosing started at 450 mg/day (1 capsule taken in the a.m. and 2 capsules taken in the p.m.), titrated to maintain plasma lithium levels of 0.4 - 0.8 milliequivalent per liter (mEq/L). The number of capsules taken per day was titrated individually for each patient based on blood testing to maintain plasma levels of lithium = 04. - 0.8 milliequivalent per liter (mEq/L).

Placebo + Riluzole

Participants randomized to placebo + riluzole were required to be taking riluzole 50 milligrams (mg) twice per day at least 30 days prior to the screening visit and during the trial. Matching placebo was supplied in 150 mg capsules. Dosing started at 450 mg/day (1 capsule in the a.m. and 2 capsules in the p.m). Paired sham dosage modifications were made for placebo subjects, i.e. all subjects randomized to placebo were 'paired' with a lithium subject and underwent identical dosage changes to maintain blinding.

Participant Flow: Overall Study

	Lithium + Riluzole	Placebo + Riluzole
STARTED	40	44
COMPLETED	36 ^[1]	38 ^[2]
NOT COMPLETED	4	6
Death	1	3
ALS Disease Progression	1	0
Withdrawal by Subject	2	2
Adverse Event	0	1

[1]	4 subjects terminated study early before 1st interim analysis. Study terminated early for futility.
[2]	6 subjects terminated study early before 1st interim analysis. Study terminated early for futility.

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Lithium + Riluzole	Subjects randomized to lithium + riluzole were required to be taking riluzole 50 milligrams (mg) twice per day at least 30 days prior to the screening visit and during the trial. Lithium carbonate and matching placebo were supplied in 150 mg capsules. Dosing started at 450 mg/day (1 capsule taken in the a.m. and 2 capsules taken in the p.m.), titrated to maintain plasma lithium levels of 0.4 - 0.8 milliequivalent per liter (mEq/L). The number of capsules taken per day was titrated individually for each patient based on blood testing to maintain plasma levels of lithium = 04. - 0.8 milliequivalent per liter (mEq/L).
Placebo + Riluzole	Participants randomized to placebo + riluzole were required to be taking riluzole 50 milligrams (mg) twice per day at least 30 days prior to the screening visit and during the trial. Matching placebo was supplied in 150 mg capsules. Dosing started at 450 mg/day (1 capsule in the a.m. and 2 capsules in the p.m). Paired sham dosage modifications were made for placebo subjects, i.e. all subjects randomized to placebo were 'paired' with a lithium subject and underwent identical dosage changes to maintain blinding.

Description

Lithium + Riluzole

Placebo + Riluzole

Baseline Measures

	Lithium + Riluzole	Placebo + Riluzole	Total
Number of Participants [units: participants]	40	44	84
Age [units: Years] Mean ± Standard Deviation	58.3 ± 10.2	55.5 ± 11.9	56.24 ± 11.16
Gender [units: participants]
Female	10	20	30
Male	30	24	54
Ethnicity (NIH/OMB) [units: Participants]
Hispanic or Latino	0	2	2
Not Hispanic or Latino	40	42	82
Unknown or Not Reported	0	0	0
Race (NIH/OMB) [units: Participants]
American Indian or Alaska Native	0	0	0
Asian	0	0	0
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	1	2	3
White	39	42	81
More than one race	0	0	0
Unknown or Not Reported	0	0	0
ALS Functional Rating Scale-Revised (ALSFRS-R) ^[1] [units: Scores on a scale] Mean ± Standard Deviation	38.4 ± 4.6	36.5 ± 5.7	37.43 ± 5.24
Vital Capacity ^[2] [units: Percent of predicted normal] Mean ± Standard Deviation	94.0 ± 18.1	86.9 ± 16.9	90.18 ± 18.20

[1]	ALSFRS-R is an ordinal rating scale questionnaire (rating 0-4) used to determine subject's assessment of their capability and independence in 12 functional activities (i.e. this is a patient-reported questionnaire scale of disability). Each question has a rating of 0-4 with 4 being the most functional and 0 being the least functional. The most functional total score is 48.
[2]	Vital capacity (VC) testing is a measure of lung function that is performed using a standard spirometer and the Slow VC method. Three trials were required (5 maximum); the best of 3 was used.

Outcome Measures

Show All Outcome Measures

1. Primary:

Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire (ALSFRS-R) [ Time Frame: 9 months: Baseline to study termination (January 2009 - October 2009) ]

Show Outcome Measure 1

2. Secondary:

Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised Questionnaire(ALSFRS-R) [ Time Frame: 9 months: Baseline to study termination (January 2009 - October 2009) ]

Show Outcome Measure 2

3. Secondary:

Vital Capacity (VC) (Percent of Predicted Normal) [ Time Frame: 9 months: Baseline to study termination (January 2009- October 2009) ]

Show Outcome Measure 3

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Elizabeth Simpson
Organization: Massachusetts General Hospital
phone: 617-726-3430
e-mail: esimpson1@partners.org

Publications:

Fornai, F., et al., Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA, 2008. 105(6): p. 2052-7.

Publications automatically indexed to this study:

Aggarwal SP, Zinman L, Simpson E, McKinley J, Jackson KE, Pinto H, Kaufman P, Conwit RA, Schoenfeld D, Shefner J, Cudkowicz M; Northeast and Canadian Amyotrophic Lateral Sclerosis consortia. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010 May;9(5):481-8. Epub 2010 Apr 1.

Responsible Party:	Merit Cudkowicz, MD, MSc, Co-Director, Neurology Clinical Trials Unit, Massachusetts General Hospital
ClinicalTrials.gov Identifier:	NCT00818389 History of Changes
Other Study ID Numbers:	U01NS049640, 3U01NS049640-04S1
Study First Received:	January 6, 2009
Results First Received:	May 10, 2010
Last Updated:	March 18, 2011
Health Authority:	United States: Federal Government; Canada: Health Canada